IMPL - Impel Neuropharma - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $19.18. This is a potential upside of $19.16 (95800%) from yesterday's end of day stock price of $0.02.

Impel Neuropharma's activity chart (see below) currently has 5 price targets and 5 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 16.67% with an average time for these price targets to be met of 40 days.

Most recent stock forecast was given by LAURA CHICO from WEDBUSH on 15-Nov-2022. First documented stock forecast 18-May-2021.

Best performing analysts who are covering IMPL - Impel Neuropharma:

Laura Chico Ken Cacciatore

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 18-May-2021

$5

$4.98 (24900.00%)

$31

3 years 4 months 18 days ago
(15-Nov-2022)

1/3 (33.33%)

$1.96 (64.47%)

80

Buy Since 03-Sep-2021

$55

3 years 4 months 19 days ago
(14-Nov-2022)

0/1 (0%)

$36.35 (194.91%)

Show more analysts

Please expand the browser size to see the chart

What is IMPL (Impel Neuropharma) average time for price targets to be met?

On average it took 40 days on average for the stock forecasts to be realized with a an average price target met ratio 16.67

Which analyst has the current highest performing score on IMPL (Impel Neuropharma) with a proven track record?

LAURA CHICO

Which analyst has the current lower performing score on IMPL (Impel Neuropharma) with a proven track record?

KEN CACCIATORE

Which analyst has the most public recommendations on IMPL (Impel Neuropharma)?

Laura Chico works at WEDBUSH and has 30 price targets and 23 ratings on IMPL

Which analyst is the currently most bullish on IMPL (Impel Neuropharma)?

Laura Chico with highest potential upside - $4.98

Which analyst is the currently most reserved on IMPL (Impel Neuropharma)?

Ken Cacciatore with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?